A review of atomoxetine effects in young people with developmental disabilities

Research in Developmental Disabilities

Volumn 35, Issue 6, 2014, Pages 1412-1424

  Aman, Michael G ^a   Smith, Tristram ^b   Arnold, L Eugene ^a   Corbett Dick, Patricia ^b   Tumuluru, Rameshwari ^c   Hollway, Jill A ^a   Hyman, Susan L ^b   Mendoza Burcham, Marissa ^c   Pan, Xueliang ^d   Mruzek, Daniel W ^b   Lecavalier, Luc ^a   Levato, Lynne ^b   Silverman, Laura B ^b   Handen, Benjamin ^c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Atomoxetine (Strattera); Autism spectrum disorders; Developmental disabilities; Review

Indexed keywords

ATOMOXETINE; GUANFACINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ABNORMAL BEHAVIOR; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIORAL SCIENCE; COGNITION; DECREASED APPETITE; DEPRESSION; DEVELOPMENTAL DISORDER; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; EYE IRRITATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HUMAN; INTELLECTUAL IMPAIRMENT; IRRITABILITY; LIVER TOXICITY; MOOD DISORDER; NAUSEA; NONHUMAN; PHARMACODYNAMICS; REVIEW; SEXUAL DYSFUNCTION; SKIN IRRITATION; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SYMPTOMATOLOGY; URINE RETENTION; VOMITING; XEROSTOMIA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLICATION;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DEVELOPMENTAL DISABILITIES; HUMANS; PROPYLAMINES;

EID: 84900397168     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2014.03.006     Document Type: Review

References (42)

1. Aman M.G. Psychotropic drugs and learning problems - A selective review. Journal of Learning Disabilities 1980, 13:87-97.
2. Aman M.G., Buican B., Arnold L.E. Methylphenidate treatment in children with low IQ and ADHD: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology 2003, 13:27-38.
3. Aman M.G., Farmer C.A., Hollway J., Arnold L.E. Treatment of inattention, overactivity and impulsiveness in autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America 2008, 17:713-738.
4. Aman M.G., Pearson D.A. Monitoring and measuring drug effects. II. Behavioral, emotional, and cognitive effects. Practitioner's guide to psychoactive drugs for children and adolescents 1999, 99-164. Plenum Press, New York. 2nd ed. J.S. Werry, K. Wada (Eds.).
5. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency 1985, 89:485-491.
6. Arnold L.E., Aman M.G., Cook A.M., Witwer A.N., Hall K.L., Thompson S., et al. Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child & Adolescent 2006, 45:1196-1205.
7. Bangs M.E., Tauscher-Wisniewski S., Polzer J., Zhang S., Acharya N., Desaiah D., et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. Journal of the American Academy of Child & Adolescent Psychiatry 2008, 47:209-218.
8. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
9. Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: An open-label study. Journal of Attention Disorders. 2011, 15:684-689.
10. Cheng J.Y., Chen R.Y., Ko J.S., Ng E.M. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents - Meta-analysis and meta-regression analysis. Psychopharmacology 2007, 194:197-209.
11. Tang C., Chou W., Cheng A.T.A. Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardationJT Journal of Child and Adolescent Psychopharmacology 2009, 19:319-320.
12. Dell'Agnello G., Zuddas A., Masi G., Curatolo P., Besana D., Rossi A. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 2009, 23:739-753.
13. Emerson E. Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. Journal of Intellectual Disability Research 2003, 47:51-58.
14. Fernández -Jaén A., Fernández -Mayoralas D.M., Pérez B.C., Muñoz-Jareño N., Campos-Diáz M. Atomoxetine for attention deficit hyperactivity disorder in mental retardation. Pediatric Neurology 2010, 43:341-347.
15. Gabriel A., Violato C. Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): An open-label study. Attention Deficit Hyperactivity Disorders 2011, 3:319-326.
16. Garnock-Jones K., Keating G. Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatric Drugs 2009, 11:203-226.
17. Greenhill L.L., Newcorn J.H., Gao H., Feldman P.D. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. Journal of the American Academy of Child & Adolescent Psychiatry 2007, 46:566-572.
18. Hammerness P., McCarthy K., Mancuso E., Gendron C., Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: A review. Neuropsychiatric Disease and Treatment 2009, 5:215.
19. Handen B.L., Gilchrist R. Practitioner review: Psychopharmacology in children and adolescents with mental retardation. Journal of Child Psychology and Psychiatry 2006, 47:871-882.
20. Harfterkamp M., van de Loo-Neus G., Minderaa R.B., van der Gaag R-J., Escobar R., Schacht A., et al. A Randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2012, 5:733-741.
21. Harfterkamp M., Buitelaar J.K., Minderaa R.B., van de Loo-Neus G., van der Gaag R-J., Hoekstra P.J. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: An open-label extension study. Journal of Child and Adolescent Psychopharmacology 2013, 23:194-199.
22. Hollway J.A., Aman M.G. Sleep correlates of pervasive developmental disorders: A review of the literature. Research in Developmental Disabilities 2011, 32:1399-1421.
23. Jou R.J., Handen B.L., Hardan A.Y. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 2005, 15:325-330.
24. King S., Griffin S., Hodges Z., Weatherly H., Asseburg C., Richardson G., et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. International Health Technology Assessment 2006, 10 iii-iv, xiii-146(Review).
25. Kratochvil C., Milton D., Vaughan B., Greenhill L. Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. Child and Adolescent Psychiatry and Mental Health 2008, 2:25.
26. Kratochvil C.J., Wilens T.E., Greenhill L.L., Gao H., Baker K.D., Feldman P.D., et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2006, 45:919-927.
27. Mazzone L., Reale L., Mannino V., Cocuzza M., Vitiello B. Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs 2011, 25:503-509.
28. Posey D.J., Wiegand R.E., Wilkerson J., Maynard M., Stigler K.A., McDougle C.J. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 2006, 16:599-610.
29. Ravindran L.N., Kim D.S., Letamendi A.M., Stein M.B. Adjunctive treatment in adults to SSRI: A randomized controlled trial of atomoxetine in generalized social anxiety disorder. Journal of Clinical Psychopharmacology 2009, 29:561-564.
30. Aman M.G., Arnold L.E., Ramadan Y., Witwer A., Lindsey R., McDougle C.J., et al. A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Archives of General Psychiatry 2005, 62:1266-1274. Research Units on Pediatric Psychopharmacology Autism Network.
31. Sauer J., Ring B., Witcher J. Clinical pharmacokinetics of atomoxetine. Clinical Pharmacokinetics 2005, 44:571-590.
32. Sauer J., Long A., Ring B., Gillespie J., Sanburn N., DeSante N., et al. Atomoxetine hydrochloride: Clinical drug-drug interaction prediction and outcome. Journal of Pharmacology and Experimental Therapeutics 2004, 302:410-418.
33. Sauer J., Ponsler G., Mattiuz E., Long A., Witcher J., Thomasson H., et al. Disposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolism. Drug Metabolism & Disposition 2003, 31:98-107.
34. Strømme P., Diseth T.H. Prevalence of psychiatric diagnoses in children with mental retardation: Data from a population-based study. Developmental Medicine & Child Neurology 2000, 42:266-270.
35. Swanson C.J., Perry K.W., Koch-Krueger S., Katner J., Svensson K.A., Bymaster F.P. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006, 50:755-760.
36. Schwartz S., Correll C.U. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: Results from a comprehensive meta-analysis and metaregression. Journal of the American Academy of Child and Adolescent Psychiatry 2014, 53:174-186.
37. Troost P.W., Steenhuis M.P., Tuynman-Qua H.G., Kalverdijk L.J., Buitelaar J.K., Minderaa R.B., et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. Journal of Child and Adolescent Psychopharmacology 2006, 16:611-619.
38. Wernicke J.F., Faries D., Girod D., Brown J.W., Gao H., Kelsey D., et al. Cardiovascular effects of atomoxetine in children, adolescents and adults. Drug Safety 2003, 26:729-740.
39. Witcher J., Long A., Smith B., Sauer J., Heilgenstein J., Wilens T., et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 2003, 13:53-63.
40. Wilens T.E., Kratochvil C., Newcorn J.H., Gao H. Do children and adolescents with ADHD respond differently to atomoxetine?. Journal of the American Academy of Child & Adolescent Psychiatry 2006, 45:149-157.
41. Young J.L., Sarkis E., Qiao M., Wietecha L. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: A 24-week, randomized, double-blind, placebo-controlled trial. Clinical Neuropharmacology 2011, 34:51-60.
42. Zeiner P., Gjevik E., Weidle B. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Pediatrica 2011, 100:1258-1261.